Advisory Board August 28, 2024
GLP-1 drugs have been approved to treat diabetes and obesity, but new research suggests that they could also have other health benefits, including helping prevent diabetes and reducing the risk of cancer.
Cheat sheet: Cardiometabolic care models
GLP-1 drugs could reduce the risk of type 2 diabetes
Last week, Eli Lilly announced that its GLP-1 drug, tirzepatide, significantly reduced the risk of developing type 2 diabetes in adults with prediabetes who were overweight or obese. Tirzepatide has been approved to treat diabetes under the brand name Mounjaro and obesity under the brand name Zepbound.
In a study, participants received weekly injections of tirzepatide for over three years. In the end, people who received tirzepatide reduced the risk of progression...
Today's Sponsors
Today's Sponsor